Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04641182
Other study ID # 0001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 6, 2020
Est. completion date September 16, 2020

Study information

Verified date November 2020
Source Pontificia Universidad Catolica de Chile
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of this observational study is to evaluate the physiological and clinical effects of prone position in awake patients with respiratory failure due to COVID-19.


Description:

The purpose of this study is to investigate the role of prone positioning in SARS-CoV-2 infected patients that are not intubated. Prone patient placement during invasive mechanical ventilation is a widespread practice in the management of severe ARDS. However, few attempts have been made to implement the prone position in patients that spontaneously ventilate with supplemental oxygen. Considering that it is a procedure that does not require additional equipment and does not represent an additional cost for its implementation, it becomes a valuable tool in the context of COVID-19 where intubation is associated with high mortality. The investigators will analyze a cohort of patients with COVID-19 and respiratory failure managed with prone position as indicated by the attending physician and register physiological variables and clinical outcomes (intubation and death).


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date September 16, 2020
Est. primary completion date August 16, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Hospitalized patients with confirmed or suspected COVID-19 pneumonia requiring more than 3 liters per minute of supplemental oxygen or a Fraction of Inspired Oxygen (FIO2) over 35% to keep Pulse Oximetry Saturation (SpO2) over 90% - Treating physician indicated prone position as instructed by the institutional protocol - Patient capable of changing position with minimal help from the personnel Exclusion Criteria: - Patient requiring immediate intubation - Patient requiring non-invasive mechanical ventilation - Respiratory Rate > 40, signs of respiratory fatigue or unconsciousness with inability to protect the airway - PaCO2 > 50mmHg - Hemodynamic instability (defined by Heart Rate > 120, Systolic Pressure < 90mmHg, Mean Arterial Pressure < 60mmHg or requiring vasopressor support) - Obesity with BMI > 40 (Body Mass Index: weight in kilograms and height in meters will be combined to attain BMI in kg/m2) - Persistent vomiting - Facial or thoracic trauma or recent surgery contraindicating the prone position - Pregnancy > 20 weeks

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Prone position
Prone position as indicated by the treating physician as specified in the institutional protocol

Locations

Country Name City State
Chile Hospital Clinico Red de Salud UC - Christus Santiago Region Metropolitana

Sponsors (1)

Lead Sponsor Collaborator
Pontificia Universidad Catolica de Chile

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Other Dyspnea Using a scale from 1 to 10 (from 1 no dyspnea to 10 maximum dyspnea) At 28 days
Other Comfort with the position Using a scale from 1 to 4 (1 is very comfortable and 4 is very uncomfortable) At 28 days
Other Oxygen saturation Using PAFI (PAFI: Index calculated by Pressure of Arterial Oxygen / Inspired Fraction of Oxygen) At 28 days
Other Oxygen saturation Using SAFI (SAFI: Index calculated by Oxygen Saturation by Pulse Oximetry / Inspired Fraction of Oxygen) At 28 days
Primary Therapeutic failure Defined by death or intubation or use of non-invasive ventilation At 14 days
Primary Mortality Number of patients that die At day 28
Primary Length of hospital stay Number of days spent by the patients at the hospital At 28 days
Primary Days requiring high flow nasal oxygen Number of days the patients require high flow nasal oxygen therapy At 28 days
Primary Days requiring supplemental oxygen Number of days the patients require supplementary oxygen At 28 days
Primary Displacement of invasive devices during position changes Unintentional displacement or removal of Invasive devices including : central and peripheric vascular catheters, urinary catheter and chest tubes At 28 days
Primary Occurrence of pressure ulcers on the anterior surface of the body Number of patients that develope pressure ulcers on the anterior surface of the body At 28 days
Secondary Respiratory superinfection Certified by a respiratory tract sample and culture At 28 days
Secondary Delirium Defined by the Confusion Assessment Method (CAM) At 28 days
Secondary Caloric intake Daily number of ingested calories (in kilocalories) by the patients is recorded At 28 days
Secondary Proteic intake Daily number of ingested proteins (in grams) by the patients is recorded At 28 days
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3